Is there an association between liraglutide use and female breast cancer in a real-world setting?

BACKGROUND: Liraglutide is a human glucagon-like peptide-1 receptor agonist approved for treatment of adults with type 2 diabetes mellitus at a maximum dose of 1.8 mg/day (Victoza(®)) and more recently at 3.0 mg/day for weight management (Saxenda(®)). During the evaluation of liraglutide for approva...

Descripción completa

Detalles Bibliográficos
Autores principales: Funch, Donnie, Mortimer, Kathleen, Li, Ling, Norman, Heather, Major-Pedersen, Atheline, Olsen, Anne Helene, Kaltoft, Margit S, Dore, David D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254592/
https://www.ncbi.nlm.nih.gov/pubmed/30538516
http://dx.doi.org/10.2147/DMSO.S171503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254592/
https://www.ncbi.nlm.nih.gov/pubmed/30538516
http://dx.doi.org/10.2147/DMSO.S171503

Ejemplares similares